S. Olbricht

1.4k total citations · 1 hit paper
14 papers, 887 citations indexed

About

S. Olbricht is a scholar working on Reproductive Medicine, Surgery and Oncology. According to data from OpenAlex, S. Olbricht has authored 14 papers receiving a total of 887 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Reproductive Medicine, 8 papers in Surgery and 7 papers in Oncology. Recurrent topics in S. Olbricht's work include Ovarian cancer diagnosis and treatment (12 papers), Intraperitoneal and Appendiceal Malignancies (8 papers) and Cancer Treatment and Pharmacology (4 papers). S. Olbricht is often cited by papers focused on Ovarian cancer diagnosis and treatment (12 papers), Intraperitoneal and Appendiceal Malignancies (8 papers) and Cancer Treatment and Pharmacology (4 papers). S. Olbricht collaborates with scholars based in Germany and France. S. Olbricht's co-authors include Andreas du Bois, Rainer Kimmig, Uwe Wagner, Walther Kuhn, Hans‐Joachim Lück, Jacobus Pfisterer, Justine Rochon, Christian Jackisch, Tien Le and Annamaria H. Zimmermann and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and European Journal of Cancer.

In The Last Decade

S. Olbricht

14 papers receiving 855 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Gemcitabine Plus Carboplatin Compared With Carboplatin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer: An Intergroup Trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG

2006 540 citations Jacobus Pfisterer, Marie Plante et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by S. Olbricht

Since Specialization

Citations

This map shows the geographic impact of S. Olbricht's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S. Olbricht with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S. Olbricht more than expected).

Fields of papers citing papers by S. Olbricht

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S. Olbricht. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S. Olbricht. The network helps show where S. Olbricht may publish in the future.

Co-authorship network of co-authors of S. Olbricht

This figure shows the co-authorship network connecting the top 25 collaborators of S. Olbricht. A scholar is included among the top collaborators of S. Olbricht based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S. Olbricht. S. Olbricht is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

#	Work	Indexed citations
1	Wer hat größere Furcht vor einer Verkürzung der Lebensspanne: palliativ oder kurativ behandelte Krebspatienten? 2009 ·PPmP - Psychotherapie · Psychosomatik · Medizinische Psychologie ·(unknown), Julia Lange, B. Anger, S. Olbricht, (unknown), Jörg Frommer	7
2	Topotecan versus treosulfan, an alkylating agent, in patients with epithelial ovarian cancer and relapse within 12 months following 1st-line platinum/paclitaxel chemotherapy. A prospectively randomized phase III trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR) 2009 ·Gynecologic Oncology ·Werner Meier, Andreas du Bois, Alexander Reuß, Walther Kuhn, S. Olbricht, M. Gropp, Barbara Richter, Hans‐Joachim Lück, Rainer Kimmig, Jacobus Pfisterer	45
3	Gemcitabine Plus Carboplatin Compared With Carboplatin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer: An Intergroup Trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG breakdown → 2006 ·Journal of Clinical Oncology ·Jacobus Pfisterer, Marie Plante, Ignace Vergote, Andreas du Bois, Hal W. Hirte, Ángel J. Lacave, Uwe Wagner, (unknown), Gavin Stuart, Rainer Kimmig, S. Olbricht, Tien Le, Janusz Emerich, Walther Kuhn, J. Bentley, Christian Jackisch, Hans‐Joachim Lück, Justine Rochon, Annamaria H. Zimmermann, Elizabeth A. Eisenhauer	540
4	Addition of Epirubicin As a Third Drug to Carboplatin-Paclitaxel in First-Line Treatment of Advanced Ovarian Cancer: A Prospectively Randomized Gynecologic Cancer Intergroup Trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens 2006 ·Journal of Clinical Oncology ·Andreas du Bois, B. Weber, Justine Rochon, Werner Meier, A Goupil, S. Olbricht, (unknown), Walther Kuhn, Hubert Orfeuvre, Uwe Wagner, Barbara Richter, Hans-Joachim Lueck, Jacobus Pfisterer, Serban Dan Costa, W. Schroeder, Rainer Kimmig, Éric Pujade-Lauraine	137
5	Epirubicin/paclitaxel/carboplatin (TEC) vs paclitaxel/carboplatin (TC) in first-line treatment of ovarian cancer FIGO stages IIB-IV. Results of a randomized AGO-GINECO GCIG Intergroup phase III trial 2005 ·International Journal of Gynecological Cancer ·Éric Pujade-Lauraine, Andreas du Bois, A Goupil, Justine Rochon, Volker Möbus, Barbara L. Weber, S. Olbricht, (unknown), M Warm, Barbara Richter	3
6	A phase II study of paclitaxel, carboplatin, and gemcitabine in previously untreated patients with epithelial ovarian cancer FIGO stage IC–IV (AGO-OVAR protocol OVAR-8) 2004 ·Gynecologic Oncology ·Andreas du Bois, Antje Belau, Uwe Wagner, (unknown), Barbara Schmalfeldt, Barbara Richter, (unknown), Christian Jackisch, Hans-Joachim Lueck, W. Schroeder, Alexander Burges, S. Olbricht, (unknown)	22
7	005 Topotecan Versus Treosulfan in Early Recurrent Ovarian Cancer After Primary Platinum/ Paclitaxel Chemotherapy. A Prospective Randomized Phase III Trial of The Ago Ovarian Cancer Study Group 2004 ·International Journal of Gynecological Cancer ·Werner Meier, Andreas du Bois, (unknown), W. Kühn, M. Gropp, (unknown), Rainer Kimmig, S. Olbricht, Uwe Wagner, Barbara Richter, Volker Moebus	8
8	39 Topotecan versus treosulfan in recurrent ovarian cancer after initial chemotherapy with platinum and paclitaxel. a prospective randomised phase III study of the AGO ovarian cancer study group 2003 ·European Journal of Cancer Supplements ·S. Loibl, Werner Meier, Andreas du Bois, W Kühn, (unknown), Rainer Kimmig, S. Olbricht, Barbara Richter	3
9	Chemotherapy versus hormonal treatment in platinum- and paclitaxel-refractory ovarian cancer: a randomised trial of the German Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group Ovarian Cancer 2002 ·Annals of Oncology ·Andreas du Bois, Werner Meier, Hans‐Joachim Lück, Günter Emons, Volker Moebus, W. Schroeder, Serban Dan Costa, Thomas Bauknecht, S. Olbricht, Christian Jackisch, Barbara Richter, Uwe Wagner	41
10	Cisplatin/paclitaxel vs. carboplatin/paclitaxel in 798 patients with ovarian cancer FIGO IIB-IV — Randomized phase III study the AGO (Arbeitsgemeinschaft Gynaekologische Onkologie) study group (OVAR-3 trial) 2001 ·European Journal of Cancer ·(unknown), Andreas du Bois, Hans-Joachim Lueck, Werner Meier, Volker Moebus, Thomas Bauknecht, Barbara Richter, W. Schroeder, (unknown), S. Olbricht	5
11	Treatment of patients with advanced ovarian cancer (FIGO IIb-IV) with cisplatin/paclitaxel or carboplatin/paclitaxel — An interim analysis of the ago study protocol ovar-3 1999 ·European Journal of Cancer ·W. Schröder, Andreas du Bois, W Kühn, (unknown), Volker Möbus, Werner Meier, (unknown), S. Olbricht, (unknown)	3
12	Carboplatin plus paclitaxel as first-line chemotherapy in previously untreated advanced ovarian cancer. German AGO Study Group Ovarian Cancer. Arbeitsgemeinschaft Gynäkologische Onkologie. 1997 ·PubMed ·Andreas du Bois, Hans‐Joachim Lück, Werner Meier, (unknown), Serban Dan Costa, Barbara Richter, T. Bauknecht, Mathias Warm, Wolfgang Schroeder, S. Olbricht, Ulrike Nitz, C Jackisch	8
13	Weekly paclitaxel with epirubicin as second-line therapy of metastatic breast cancer: results of a clinical phase II study. 1997 ·PubMed ·Uwe Köhler, S. Olbricht, (unknown), E. Kettner, Barbara Richter, Karsten Ridwelski	16
14	Carboplatin/paclitaxel versus cisplatin/paclitaxel as first-line chemotherapy in advanced ovarian cancer: an interim analysis of a randomized phase III trial of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group. 1997 ·PubMed ·Andreas du Bois, (unknown), Werner Meier, Volker Möbus, (unknown), Barbara Richter, M Warm, T. Bauknecht, Wolfgang Schröder, S. Olbricht, (unknown), C Jackisch	49

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact